RBN-3143 is under clinical development by Ribon Therapeutics and currently in Phase I for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase I drugs for Atopic Dermatitis (Atopic Eczema) have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RBN-3143’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RBN-3143 is under development for the treatment of atopic dermatitis, scleroderma, ulcerative colitis, and asthma. The drug candidate developed based on Beacon platform. It is administered through oral route in the form of tablet. It acts by targeting poly-ADP ribose polymerase 14 (PARP 14) enzyme.
Ribon Therapeutics overview
Ribon Therapeutics is a biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions. The company leverages a chemical biology approach and its proprietary discovery platform for building a pipeline of small molecule inhibitors to numerous NAD+ utilizing enzymes includes monoPARPs, which have applications across multiple therapeutic areas. Its lead program is developing PARP7 inhibitors for the treatment of cancer. Ribon Therapeutics explores novel areas of disease biology and enzyme families for drug discovery and development of new treatments for patients with high unmet needs. The company is funded by including The Column Group, life science investors, U.S. Venture Partners, Deerfield Management and Osage University Partners. Ribon Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of RBN-3143’s drug-specific PTSR and LoA scores, buy the report here.